Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print Created with Sketch. YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Please Log In/Join Now first, and then use this function!

Recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma - CC-220-MM-001

Updated: 9 May, 2022   |   ClinicalTrials.gov

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 53

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Cohort A: CC-220 Monotherapy - Part 1
Drug: CC-220
Experimental: Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1
Drug: CC-220 Drug: Dexamethasone
Experimental: Cohort C: CC-220 Monotherapy in RRMM
Drug: CC-220
Experimental: Cohort D: CC-220 in combination with Dexamethasone - Part 2
Drug: CC-220 Drug: Dexamethasone
Experimental: Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1
Drug: Dexamethasone Drug: Daratumumab- 1800mg Drug: CC-220 Drug: Daratumumab
Experimental: Cohort F: CC-220 with DEX and bortezomib - Part 1
Drug: Dexamethasone Drug: Bortezomib Drug: CC-220
Experimental: Cohort G1: CC-220 in combination with CFZ and DEX - Part 1
Drug: CC-220 Drug: Dexamethasone Drug: Carfilzomib
Experimental: Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1
Drug: CC-220 Drug: Dexamethasone Drug: Carfilzomib
Experimental: Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2
Drug: CC-220 Drug: Dexamethasone
Experimental: Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2
Drug: Dexamethasone Drug: CC-220 Drug: Bortezomib
Experimental: Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2
Drug: Dexamethasone Drug: Bortezomib Drug: CC-220
Experimental: Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible
Drug: CC-220 Drug: Dexamethasone Drug: Daratumumab

Key Eligibility Criteria

Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 - Relapsed and refractory multiple myeloma (RRMM) participants must have documented disease progression on or within 60 days from the last dose of their last myeloma therapy - Newly diagnosed multiple myeloma (NDMM) participants must have documented diagnosis with previously untreated symptomatic multiple myeloma (MM) - Participants in Cohorts J1 and K are those for whom autologous stem cell transplantation is not planned for initial therapy or are not considered by the investigator as eligible for high-dose chemotherapy and autologous stem cell transplantation Exclusion Criteria: - Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study - Nonsecretory multiple myeloma - Prior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years Other protocol-defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com